Printer Friendly

AMERICAN CYANAMID, HOUGHTEN PHARMACEUTICALS SIGN RESEARCH COLLABORATION AGREEMENT

 SAN DIEGO, March 22 /PRNewswire/ -- American Cyanamid's (NYSE: ACY) Agricultural Research Division and Houghten Pharmaceuticals Inc. (HPI) announced today they have signed a research collaboration agreement.
 Under terms of the agreement, HPI will provide Cyanamid with synthetic combinatorial libraries for rapid screening of Cyanamid's proprietary assays in animal health and agricultural fields. HPI's screening technology enables researchers to rapidly screen hundreds of millions of compounds and significantly decrease the time and cost of identifying lead compounds in the drug discovery process.
 Dr. Richard Houghten, chief executive officer and founder of HPI, said the research collaboration provides HPI with milestone payments and royalties on sales of agricultural and animal health products developed by Cyanamid.
 "HPI will retain rights to compounds that may have applications in human therapeutics," Houghten said. "Cyanamid will receive milestone payments and royalties on any human medical products developed by HPI resulting from the collaboration."
 Specific terms of the agreement were not disclosed.
 Cyanamid's Agricultural Research Division is a world leader in the design of novel high-capacity screens for agricultural research and development. According to Dr. Lantz Crawley, vice president, discovery, of Cyanamid's Agricultural Research Division, "In our search for leads which target novel biochemical pathways, we evaluate more organic compounds and natural products than any other company in the world.
 "With our screens, access to HPI's combinatorial peptide libraries should allow us to rapidly detect unique leads or products," Crawley said. "We are excited about our cooperation with Houghten Pharmaceuticals in this area, and both companies should benefit."
 Founded in 1990, HPI is actively pursuing breakthrough technologies in chemical screenings libraries for other areas of drug discovery. In addition, through its wholly owned subsidiary, Multiple Peptide Systems, HPI offers custom peptides and related products using its good manufacturing practices (GMP) synthesis capability. Corporate offices, laboratories and manufacturing facilities are in Torrey Pines Business and Research Park, San Diego.
 Cyanamid is a research-based life sciences and chemical company which discovers and develops medical, agricultural and chemical products and manufactures and markets them in more than 135 countries. Its shares (ACY) trade on the New York Stock Exchange.
 -0- 3/22/93
 /CONTACT: Tom Gable or Julie Smutko, 619-234-1300, or Charles Versaggi, 408-358-4162, all of Gable Versaggi BioCommunications, for Houghten Pharmaceuticals/
 (ACY)


CO: American Cyanamid; Houghten Pharmaceuticals Inc. ST: California IN: MTC SU:

JB-LS -- SD002 -- 8296 03/22/93 14:40 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 22, 1993
Words:393
Previous Article:DUPONT SPONSORS TEACHERS AT NSTA
Next Article:SFFED RELEASES FEBRUARY CONSOLIDATED FINANCIAL HIGHLIGHTS
Topics:


Related Articles
P&G AND HOUGHTEN PHARMACEUTICALS INC. SIGN JOINT RESEARCH AGREEMENT
GLAXO INC., HOUGHTEN PHARMACEUTICALS SIGN JOINT RESEARCH, DEVELOPMENT AGREEMENT USING PATENTED PEPTIDE TECHNOLOGY IN DRUG DISCOVERY
HAUSER ANNOUNCES PACLITAXEL RESEARCH & COMMERCIALIZATION AGREEMENTS
HOUGHTEN PHARMACEUTICALS INC. AND NORTHWEST NEUROLOGIC INC. SIGN RESEARCH & LICENSE AGREEMENT FOR RESEARCH COLLABORATION
P&G AND HOUGHTEN PHARMACEUTICALS INITIATE THIRD DRUG DISCOVERY ALLIANCE
DURA PHARMACEUTICALS, INC. SIGNS COLLABORATIVE AGREEMENT WITH HOUGHTEN PHARMACEUTICALS, INC.
American Cyanamid and LSU Sign Licensing Agreement for Herbicide Tolerant Rice
Monsanto and Cyanamid Announce Glyphosate Supply Agreement.
American Cyanamid and Hyseq Sign Broad Scale Gene Product Agreement.
OSI Pharmaceuticals Licenses American Cyanamid's Yeast GPCR Technology In Patent Cross-Licensing Agreement.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters